Moreover, the analysis of drug response genomewide microarray data reveals that high doses of yohimbine can activate BAG6 in stage 1 bladder cancer, while high doses of chlorpromazine can activate HSPA5 and JUN in stage 4 bladder cancer.
The major factors, including downregulated miR12, the aging-related proteins, HSP90B1, CALR, HSPA5, PDIA3, RPN1, and ECT2, the smoking-related proteins, HUWE1, HSPA5, and ECT2, and the epigenetic regulation of ENO1, HSP90B1, CALR, and PDIA3, lead to the progression from normal bladder cells to stage 1 bladder cancer cells through the SUP and ER signaling pathways.
Stage 1 bladder Stage 4 bladder cancer cancer The highly expressed ADRM1, COPS5, PSMD8, ADRM1, COPS5, PSMD8, genes for potential SUMO2, CALR, PDIA3, SUMO2, RNF126, CALR, inhibition strategy DNAJB11, HSPA5, RPN1, PDIA3, DNAJB11, of multiple drug CUL1, HSP90B1, KPNA2, HSPA5, RPN1, design PSMD12, ECT2, TK1, HSP90AA1, HSPA1B, TUBA1C, HN1, and ENO1 METTL23, RARRES3, KPNA2, PSMD12, ECT2, JUN, TK1, TUBA1C, HN1, and ENO1 The suppressed genes UBC, JUN, RARRES3, BCL3, FOS, UBC, and for potential and FOS GTF2A1 activation strategy of multiple drug design The BAG6, HUWE1, PAAF1, BAG6, HUWE1, PAAF1, nondifferentially PSMD10, FAF2, PCYT1A, PSMD10, FAF2, PCYT1A, expressed genes to and PSMD10 and PSMD10 avoid side-effect of multiple drug design The potential multiple drug combination
